RJA
HALO icon

Raymond James & Associates’s Halozyme HALO Stock Holding History

Raymond James & Associates’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$15.7M Buy
273,591
+127,330
+87% +$7.3M 0.01% 954
2024
Q2 		$7.66M Buy
146,261
+49,923
+52% +$2.19M 0.01% 1323
2024
Q1 		$3.92M Buy
96,338
+25,674
+36% +$962K ﹤0.01% 1754
2023
Q4 		$2.61M Sell
70,664
-6,657
-9% -$251K ﹤0.01% 1940
2023
Q3 		$2.95M Sell
77,321
-583
-0.7% -$23.9K ﹤0.01% 1782
2023
Q2 		$2.81M Sell
77,904
-29,073
-27% -$992K ﹤0.01% 1852
2023
Q1 		$4.09M Buy
106,977
+2,577
+2% +$121K ﹤0.01% 1601
2022
Q4 		$5.94M Buy
104,400
+29,546
+39% +$1.51M 0.01% 1299
2022
Q3 		$2.96M Buy
74,854
+33,149
+79% +$1.47M ﹤0.01% 1723
2022
Q2 		$1.83M Buy
41,705
+8,304
+25% +$359K ﹤0.01% 2035
2022
Q1 		$1.33M Sell
33,401
-17,793
-35% -$634K ﹤0.01% 2405
2021
Q4 		$2.06M Buy
51,194
+16,049
+46% +$599K ﹤0.01% 2155
2021
Q3 		$1.43M Sell
35,145
-662
-2% -$27.7K ﹤0.01% 2343
2021
Q2 		$1.63M Buy
35,807
+5,597
+19% +$248K ﹤0.01% 2247
2021
Q1 		$1.26M Sell
30,210
-17,940
-37% -$819K ﹤0.01% 2342
2020
Q4 		$2.06M Buy
48,150
+17,585
+58% +$632K ﹤0.01% 1876
2020
Q3 		$803K Buy
30,565
+7,922
+35% +$221K ﹤0.01% 2313
2020
Q2 		$607K Buy
22,643
+645
+3% +$14.6K ﹤0.01% 2463
2020
Q1 		$396K Sell
21,998
-1,815
-8% -$34.5K ﹤0.01% 2578
2019
Q4 		$422K Buy
23,813
+84
+0.4% +$1.46K ﹤0.01% 2849
2019
Q3 		$368K Buy
+23,729
New +$391K ﹤0.01% 2871
2018
Q4 		– Sell
-14,988
Closed -$272K – 3616
2018
Q3 		$272K Buy
14,988
+1,837
+14% +$32.2K ﹤0.01% 3102
2018
Q2 		$222K Buy
+13,151
New +$249K ﹤0.01% 3201
2018
Q1 		– Sell
-10,685
Closed -$216K – 3509
2017
Q4 		$216K Buy
+10,685
New +$196K ﹤0.01% 3011
2016
Q4 		– Sell
-11,770
Closed -$142K – 3300
2016
Q3 		$142K Buy
11,770
+100
+0.9% +$1.02K ﹤0.01% 2941
2016
Q2 		$101K Sell
11,670
-300
-3% -$2.96K ﹤0.01% 2802
2016
Q1 		$113K Hold
11,970
– – ﹤0.01% 2697
2015
Q4 		$207K Sell
11,970
-4,600
-28% -$73.3K ﹤0.01% 2316
2015
Q3 		$223K Buy
16,570
+370
+2% +$7.43K ﹤0.01% 2229
2015
Q2 		$366K Sell
16,200
-14,050
-46% -$247K ﹤0.01% 2213
2015
Q1 		$432K Buy
30,250
+2,850
+10% +$41.1K ﹤0.01% 2099
2014
Q4 		$264K Buy
27,400
+3,700
+16% +$32.9K ﹤0.01% 2156
2014
Q3 		$216K Buy
23,700
+1,500
+7% +$14.3K ﹤0.01% 2133
2014
Q2 		$219K Buy
22,200
+5,800
+35% +$49.2K ﹤0.01% 2143
2014
Q1 		$208K Buy
16,400
+400
+3% +$5.94K ﹤0.01% 2064
2013
Q4 		$240K Buy
+16,000
New +$206K ﹤0.01% 1916

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Raymond James & Associates's HALO Position: Q3 2024 in Review

Raymond James & Associates increased its Halozyme (HALO) stake by 87% in Q3 2024, buying an estimated $7.3M and bringing the position to 273,591 shares worth $15.7M. The position accounts for 0.01% of the portfolio, ranked #954.

Raymond James & Associates first reported a position in HALO in Q4 2013 and has held it in 36 quarters since. 508 funds tracked by Wall St. Rank hold HALO as of Q3 2024.

  • Raymond James & Associates held 273,591 shares of Halozyme worth $15.7M as of Q3 2024.
  • Raymond James & Associates bought 127,330 Halozyme shares in Q3 2024, an estimated $7.3M.
  • Halozyme made up 0.01% of Raymond James & Associates's portfolio in Q3 2024, its #954 holding.
  • Raymond James & Associates first reported a position in Halozyme in Q4 2013 and has held it in 36 quarters since.
  • 508 funds tracked by Wall St. Rank held Halozyme as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.